US 12,064,599 B2
Management of insufficient hypoglycemia response
Di Wu, Glendale, CA (US); Rebecca K. Gottlieb, Culver City, CA (US); Benyamin Grosman, Winnetka, CA (US); Anirban Roy, Agoura Hills, CA (US); Neha J. Parikh, West Hills, CA (US); and Ohad Cohen, Kiryat Uno (IL)
Assigned to MEDTRONIC MINIMED, INC., Northridge, CA (US)
Filed by Medtronic MiniMed, Inc., Northridge, CA (US)
Filed on Aug. 4, 2021, as Appl. No. 17/394,121.
Application 17/394,121 is a continuation of application No. 15/410,611, filed on Jan. 19, 2017, granted, now 11,097,051.
Claims priority of provisional application 62/417,843, filed on Nov. 4, 2016.
Prior Publication US 2021/0361866 A1, Nov. 25, 2021
Int. Cl. A61M 5/172 (2006.01); A61B 5/145 (2006.01); A61M 5/142 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/50 (2018.01)
CPC A61M 5/1723 (2013.01) [A61B 5/14532 (2013.01); A61M 5/14244 (2013.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/50 (2018.01); A61M 2005/14208 (2013.01); A61M 2205/50 (2013.01); A61M 2205/581 (2013.01); A61M 2205/583 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A system comprising:
one or more processors; and
one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:
obtaining, by a controller associated with an insulin delivery pump, an amount of insulin remaining in a body of a patient;
obtaining, by the controller, a quantity of insulin needed by the patient within a future time period;
based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period, identifying, by the controller, a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery; and
responsive to identifying the condition, causing, by the controller, performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.